LGD-4033 Solution 10mg/ml – 50ml
| Application | Selective Androgen Receptor Modulator |
| Concentration | 1% (10mg/ml) |
| Composition | 99% PEG400, 1% LGD-4033 (>99% purity) |
| CAS | 1165910-22-4 |
| Molar Mass | 338.25 g/mol |
| Chemical Formula | C14H12F6N2O |
| Synonyms | LGD4033, LGD-4033, LGD4, Ligandrol, VK5211 |
| Storage | Minimize open air exposure, store in a cool dry place |
| Terms | For laboratory research use only. Not for human or animal consumption. |
What Is LGD-4033 (Ligandrol)?
LGD-4033, also known as Ligandrol or VK5211, is a non-steroidal full agonist at the androgen receptor developed by Ligand Pharmaceuticals and subsequently licensed to Viking Therapeutics. Among full-agonist SARMs, it carries the most extensive human clinical dataset — having completed Phase 1 dose-escalation and Phase 2 trials with demonstrable proof-of-concept efficacy in both healthy volunteers and hip fracture patients.
A 2010 Phase 1 trial in 76 healthy men at doses of 0.1–1.0 mg/day demonstrated dose-dependent lean body mass gains (up to ~1.21 kg at 1 mg/day over 21 days) without significant changes in PSA or hepatic enzymes. Under the name VK5211, Phase 2 trials in hip fracture patients showed significant improvements in lean body mass and physical function scores — making LGD-4033 one of the very few SARMs with clinical-stage proof-of-concept in a real disease population.
Mechanism of Action
LGD-4033 binds the androgen receptor with high affinity (Ki ~1 nM) and acts as a full agonist in skeletal muscle and bone tissue. Its selectivity over prostate and reproductive tissues is substantial, though somewhat less extreme than that of RAD-140 (which has a reported anabolic-to-androgenic ratio exceeding 90:1). The resulting anabolic gene expression profile promotes protein synthesis, nitrogen retention, and lean mass accumulation — the primary endpoints of most LGD-4033 research designs.
Research Applications
- Muscle wasting and sarcopenia: Phase 2 data in hip fracture patients provides direct clinical translation context.
- Osteoporosis: Bone formation markers respond positively in preclinical LGD-4033 models.
- Comparative SARM pharmacology: LGD-4033 is the standard full-agonist comparator in studies benchmarking against partial agonists.
- Dual-mechanism anabolic studies: Routinely combined with MK-677 (Ibutamoren) to probe simultaneous AR and GH/IGF-1 axis activation.
Related Research Compounds
LGD-4033 is most directly compared to RAD-140 for potency and selectivity, and to MK-2866 (Ostarine) as the partial-agonist reference compound with the largest human dataset. In metabolic research designs, GW501516 (Cardarine) and SR9009 are commonly added to explore metabolic endpoints alongside anabolic signaling.
Read our research guide: LGD-4033 (Ligandrol) Research Guide: Human Trials, Pharmacology & Comparisons | RAD-140 vs LGD-4033: Comparing Two Leading SARMs.
For laboratory research use only. Not for human or animal consumption.
Reviews
There are no reviews yet.